m6A Regulator and Potential Drug Response
General Information of the m6A Regulator (ID: REG00013)
| Regulator Name | Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) | ||||
|---|---|---|---|---|---|
| Synonyms |
IGF2 mRNA-binding protein 2; IMP-2; Hepatocellular carcinoma autoantigen p62; IGF-II mRNA-binding protein 2; VICKZ family member 2; IMP2; VICKZ2
Click to Show/Hide
|
||||
| Gene Name | IGF2BP2 | ||||
| Regulator Type | WRITER ERASER READER | ||||
| Regulator Link | Click to View Full Information of This Regulator | ||||
Full List of Target Gene(s) of This m6A Regulator and Corresponding Potential Drug Response(s)
Ephrin type-A receptor 2 (EPHA2)
BT5528 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for BT5528. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BT5528 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). | [1], [2] | ||
CAR-T cells targeting EphA2 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for CAR-T cells targeting EphA2. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CAR-T cells targeting EphA2 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). | [1], [3] | ||
DS-8895 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for DS-8895. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of DS-8895 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). | [1], [4] | ||
MEDI-547 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for MEDI-547. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MEDI-547 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). | [1], [5] | ||
MEDI-543 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for MEDI-543. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MEDI-543 through regulating the expression of Ephrin type-A receptor 2 (EPHA2). | [1], [6] | ||
AMP-PNP [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Ephrin type-A receptor 2 (EPHA2) is a therapeutic target for AMP-PNP. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AMP-PNP through regulating the expression of Ephrin type-A receptor 2 (EPHA2). | [1], [7] | ||
Erbb2 tyrosine kinase receptor (HER2)
Afatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Afatinib. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Afatinib through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [9] | ||
Dacomitinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Dacomitinib. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Dacomitinib through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [10] | ||
Lapatinib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Lapatinib. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Lapatinib through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [11] | ||
Margetuximab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Margetuximab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Margetuximab through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [12] | ||
Masoprocol [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Masoprocol. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Masoprocol through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [13] | ||
Merimepodib [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Merimepodib. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Merimepodib through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [14] | ||
NERATINIB MALEATE [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for NERATINIB MALEATE. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of NERATINIB MALEATE through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [15] | ||
Pertuzumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Pertuzumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Pertuzumab through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [16] | ||
Trastuzumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Trastuzumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Trastuzumab through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [17] | ||
HKI-272 [Phase 3]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for HKI-272. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of HKI-272 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [18] | ||
| Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for HKI-272. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of HKI-272 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [19] | |||
Nelipepimut S [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Nelipepimut S. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Nelipepimut S through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [20] | ||
NeuVax [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for NeuVax. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of NeuVax through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [21] | ||
PF-05280014 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for PF-05280014. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PF-05280014 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [22] | ||
Trastuzumab-DM1 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Trastuzumab-DM1. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Trastuzumab-DM1 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [23] | ||
Varlitinib [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Varlitinib. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Varlitinib through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [11] | ||
A166 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for A166. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of A166 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [24] | ||
ABY-025 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for ABY-025. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ABY-025 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [25] | ||
AGN-208397 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for AGN-208397. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AGN-208397 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [26] | ||
Anti-HER2 CAR-T [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Anti-HER2 CAR-T. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Anti-HER2 CAR-T through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [27] | ||
AU105 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for AU105. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AU105 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [18] | ||
AVX901 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for AVX901. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AVX901 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [28] | ||
AZD8931 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for AZD8931. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AZD8931 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [17] | ||
BDTX-189 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for BDTX-189. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BDTX-189 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [29] | ||
BMS-599626 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for BMS-599626. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BMS-599626 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [21] | ||
BMS-690514 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for BMS-690514. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BMS-690514 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [30] | ||
CART-HER-2 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for CART-HER-2. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CART-HER-2 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [31] | ||
CI-1033 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for CI-1033. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CI-1033 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [18] | ||
CP-724714 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for CP-724714. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CP-724714 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [32] | ||
DN24-02 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for DN24-02. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of DN24-02 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [33] | ||
Ertumaxomab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Ertumaxomab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Ertumaxomab through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [21] | ||
HER-2 Protein AutoVac [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for HER-2 Protein AutoVac. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of HER-2 Protein AutoVac through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [34] | ||
HER-2-targeting CAR T Cells [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for HER-2-targeting CAR T Cells. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of HER-2-targeting CAR T Cells through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [35] | ||
Her2-targeted autologous T-cell therapy [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Her2-targeted autologous T-cell therapy. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Her2-targeted autologous T-cell therapy through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [36] | ||
HM-78136B [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for HM-78136B. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of HM-78136B through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [37] | ||
ISB 1302 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for ISB 1302. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ISB 1302 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [38] | ||
KN026 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for KN026. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of KN026 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [39] | ||
MCLA-128 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for MCLA-128. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MCLA-128 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [40] | ||
MGAH22 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for MGAH22. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MGAH22 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [41] | ||
MM-111 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for MM-111. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MM-111 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [42] | ||
MRG002 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for MRG002. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MRG002 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [43] | ||
Sym013 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Sym013. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Sym013 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [44] | ||
Tarloxotinib [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Tarloxotinib. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Tarloxotinib through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [45] | ||
TAS-0728 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for TAS-0728. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of TAS-0728 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [46] | ||
Zenocutuzomab [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Zenocutuzomab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Zenocutuzomab through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [47] | ||
AIP-303 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for AIP-303. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AIP-303 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [48] | ||
ARRY-380 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for ARRY-380. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ARRY-380 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [45] | ||
BAY 2701439 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for BAY 2701439. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BAY 2701439 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [49] | ||
CAR-T Cells targeting HER2 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for CAR-T Cells targeting HER2. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CAR-T Cells targeting HER2 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [50] | ||
CAR-T cells targeting HER2 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for CAR-T cells targeting HER2. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CAR-T cells targeting HER2 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [51] | ||
Cipatinib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Cipatinib. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Cipatinib through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [52] | ||
CUDC-101 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for CUDC-101. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CUDC-101 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [53] | ||
DZD1516 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for DZD1516. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of DZD1516 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [54] | ||
GBR1302 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for GBR1302. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of GBR1302 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [55] | ||
GQ1001 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for GQ1001. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of GQ1001 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [56] | ||
HER2-CAR T Cells [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for HER2-CAR T Cells. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of HER2-CAR T Cells through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [18] | ||
HER2-specific CAR T cell [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for HER2-specific CAR T cell. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of HER2-specific CAR T cell through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [57] | ||
HER2-specific T cells [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for HER2-specific T cells. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of HER2-specific T cells through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [58] | ||
HER2p63-71 peptide vaccine [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for HER2p63-71 peptide vaccine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of HER2p63-71 peptide vaccine through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [59] | ||
JNJ-26483327 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for JNJ-26483327. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of JNJ-26483327 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [60] | ||
M802 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for M802. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of M802 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [61] | ||
MB-103 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for MB-103. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MB-103 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [62] | ||
MBS301 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for MBS301. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MBS301 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [63] | ||
MEDI4276 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for MEDI4276. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MEDI4276 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [64] | ||
MM-302 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for MM-302. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MM-302 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [65] | ||
MT-5111 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for MT-5111. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MT-5111 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [66] | ||
MVA HER-2 AutoVac [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for MVA HER-2 AutoVac. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MVA HER-2 AutoVac through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [67] | ||
NJH395 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for NJH395. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of NJH395 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [68] | ||
Recombinant human Erbb3 fragment therapeutic tumor vaccine [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Recombinant human Erbb3 fragment therapeutic tumor vaccine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Recombinant human Erbb3 fragment therapeutic tumor vaccine through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [69] | ||
S-222611 [Phase 1b]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for S-222611. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of S-222611 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [70] | ||
SBT6050 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for SBT6050. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of SBT6050 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [71] | ||
TAK-285 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for TAK-285. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of TAK-285 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [72] | ||
TrasGEX [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for TrasGEX. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of TrasGEX through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [73] | ||
VM-206 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for VM-206. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of VM-206 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [74] | ||
Zemab [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Zemab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Zemab through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [75] | ||
ZW49 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for ZW49. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ZW49 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [76] | ||
227Th-labelled HER2-TTC [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for 227Th-labelled HER2-TTC. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 227Th-labelled HER2-TTC through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [21] | ||
(1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for (1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of (1-Benzyl-1H-indazol-5-yl)-quinazolin-4-yl-amine through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [77] | ||
(1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine [Investigative]
| In total 2 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [78] | ||
| Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of (1-Benzyl-1H-indol-5-yl)-quinazolin-4-yl-amine through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [79] | |||
3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [80] | ||
3,4-diphenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for 3,4-diphenyl-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 3,4-diphenyl-1H-pyrrole-2,5-dione through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [81] | ||
3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [82] | ||
3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [80] | ||
4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for 4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4-(3-phenoxylphenyl)-5-cyano-2H-1,2,3-triazole through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [79] | ||
4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for 4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4-(4-bromophenyl)-5-cyano-2H-1,2,3-triazole through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [79] | ||
4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for 4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4-(4-chlorophenyl)-5-cyano-2H-1,2,3-triazole through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [79] | ||
4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for 4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4-(4-isopropylphenyl)-5-cyano-2H-1,2,3-triazole through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [80] | ||
4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for 4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4-(Bis(2-chloroethyl)amino)-N-p-tolylbenzamide through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [83] | ||
4557W [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for 4557W. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4557W through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [82] | ||
AG-213 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for AG-213. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AG-213 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [84] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for BMS 536924. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BMS 536924 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [85] | ||
CL-387785 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for CL-387785. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CL-387785 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [80] | ||
Geldanamycin-estradiol hybrid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Geldanamycin-estradiol hybrid. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Geldanamycin-estradiol hybrid through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [86] | ||
HDS-029 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for HDS-029. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of HDS-029 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [87] | ||
ISIS 12882 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for ISIS 12882. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ISIS 12882 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [88] | ||
ISIS 12883 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for ISIS 12883. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ISIS 12883 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [88] | ||
ISIS 12884 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for ISIS 12884. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ISIS 12884 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [89] | ||
ISIS 9002 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for ISIS 9002. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ISIS 9002 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [88] | ||
ISIS 9003 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for ISIS 9003. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ISIS 9003 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [88] | ||
ISIS 9005 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for ISIS 9005. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ISIS 9005 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [88] | ||
N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [78] | ||
PD-168393 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for PD-168393. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PD-168393 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [86] | ||
PF 5208766 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for PF 5208766. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PF 5208766 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [90] | ||
PNT-500 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for PNT-500. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PNT-500 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [78] | ||
Redoxal [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Redoxal. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Redoxal through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [78] | ||
TA1-RTA [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for TA1-RTA. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of TA1-RTA through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [91] | ||
GW-974 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for GW-974. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of GW-974 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [92] | ||
Her-2-Bi-armed ATC [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for Her-2-Bi-armed ATC. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Her-2-Bi-armed ATC through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [93] | ||
TAK165 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Erbb2 tyrosine kinase receptor (HER2) is a therapeutic target for TAK165. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of TAK165 through regulating the expression of Erbb2 tyrosine kinase receptor (HER2). | [8], [94] | ||
Extracellular signal-regulated kinase 1 (ERK1)
ASTX029 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for ASTX029. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ASTX029 through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [95], [96] | ||
BVD-523 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for BVD-523. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BVD-523 through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [95], [97] | ||
HH2710 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for HH2710. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of HH2710 through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [95], [98] | ||
ASN007 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for ASN007. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ASN007 through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [95], [99] | ||
GDC-0994 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for GDC-0994. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of GDC-0994 through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [18], [95] | ||
JSI-1187 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for JSI-1187. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of JSI-1187 through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [95], [100] | ||
VAN-10-4-eluting stent [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for VAN-10-4-eluting stent. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of VAN-10-4-eluting stent through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [95], [101] | ||
COR-D [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for COR-D. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of COR-D through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [95], [102] | ||
6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 1 (ERK1) is a therapeutic target for 6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 6-[(E)-2-(4-Fluoro-phenyl)-vinyl]-9H-purine through regulating the expression of Extracellular signal-regulated kinase 1 (ERK1). | [95], [103] | ||
Extracellular signal-regulated kinase 2 (ERK2)
ASTX029 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for ASTX029. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ASTX029 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [96] | ||
BVD-523 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for BVD-523. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BVD-523 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [104] | ||
HH2710 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for HH2710. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of HH2710 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [98] | ||
GDC-0994 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for GDC-0994. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of GDC-0994 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [18], [95] | ||
JSI-1187 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for JSI-1187. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of JSI-1187 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [100] | ||
LY3214996 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for LY3214996. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of LY3214996 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [99] | ||
VAN-10-4-eluting stent [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for VAN-10-4-eluting stent. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of VAN-10-4-eluting stent through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [101] | ||
COR-D [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for COR-D. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of COR-D through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [105] | ||
(4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for (4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of (4-Fluoro-phenyl)-(9-methyl-9H-purin-6-yl)-amine through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [106] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [107] | ||
AEZS-131 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for AEZS-131. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AEZS-131 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [108] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Bisindolylmaleimide-I. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [109] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for BMS 536924. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BMS 536924 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [110] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for CI-1040. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CI-1040 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [111] | ||
DEBROMOHYMENIALDISINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for DEBROMOHYMENIALDISINE. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of DEBROMOHYMENIALDISINE through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [106] | ||
ERK inhibitor III [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for ERK inhibitor III. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ERK inhibitor III through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [112] | ||
FR-180204 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for FR-180204. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of FR-180204 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [89], [95] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for KN-62. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of KN-62 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [113] | ||
KT-5720 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for KT-5720. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of KT-5720 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [112] | ||
Phosphonothreonine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Phosphonothreonine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Phosphonothreonine through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [114] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for RO-316233. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of RO-316233 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [106] | ||
Ro-4396686 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Ro-4396686. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Ro-4396686 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [106] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for Ro31-8220. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Ro31-8220 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [115] | ||
SCH772984 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for SCH772984. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of SCH772984 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [116] | ||
SB220025 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Extracellular signal-regulated kinase 2 (ERK2) is a therapeutic target for SB220025. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of SB220025 through regulating the expression of Extracellular signal-regulated kinase 2 (ERK2). | [95], [103] | ||
Fascin (FSCN1)
NP-G2-044 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Fascin (FSCN1) is a therapeutic target for NP-G2-044. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of NP-G2-044 through regulating the expression of Fascin (FSCN1). | [106], [117] | ||
Glucose transporter type 1 (SLC2A1)
D-glucose [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glucose transporter type 1 (SLC2A1) is a therapeutic target for D-glucose. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of D-glucose through regulating the expression of Glucose transporter type 1 (SLC2A1). | [118], [119] | ||
Quercetin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glucose transporter type 1 (SLC2A1) is a therapeutic target for Quercetin. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Quercetin through regulating the expression of Glucose transporter type 1 (SLC2A1). | [118], [120] | ||
2-Deoxyglucose [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glucose transporter type 1 (SLC2A1) is a therapeutic target for 2-Deoxyglucose. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 2-Deoxyglucose through regulating the expression of Glucose transporter type 1 (SLC2A1). | [118], [121] | ||
WZB-117 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glucose transporter type 1 (SLC2A1) is a therapeutic target for WZB-117. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of WZB-117 through regulating the expression of Glucose transporter type 1 (SLC2A1). | [118], [122] | ||
Arsenite [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glucose transporter type 1 (SLC2A1) is a therapeutic target for Arsenite. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Arsenite through regulating the expression of Glucose transporter type 1 (SLC2A1). | [118], [123] | ||
Dehydroascorbic acid [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Glucose transporter type 1 (SLC2A1) is a therapeutic target for Dehydroascorbic acid. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Dehydroascorbic acid through regulating the expression of Glucose transporter type 1 (SLC2A1). | [118], [124] | ||
Heparanase (HPSE)
Heparin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heparanase (HPSE) is a therapeutic target for Heparin. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Heparin through regulating the expression of Heparanase (HPSE). | [125], [126] | ||
PG-545 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heparanase (HPSE) is a therapeutic target for PG-545. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PG-545 through regulating the expression of Heparanase (HPSE). | [125], [127] | ||
Suramin [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heparanase (HPSE) is a therapeutic target for Suramin. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Suramin through regulating the expression of Heparanase (HPSE). | [125], [128] | ||
Neutralase [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Heparanase (HPSE) is a therapeutic target for Neutralase. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Neutralase through regulating the expression of Heparanase (HPSE). | [125], [129] | ||
Hepatocyte nuclear factor 1-alpha (HNF1A)
Norleucine [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hepatocyte nuclear factor 1-alpha (HNF1A) is a therapeutic target for Norleucine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Norleucine through regulating the expression of Hepatocyte nuclear factor 1-alpha (HNF1A). | [130], [131] | ||
Hexokinase-2 (HK2)
VDA-1102 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Hexokinase-2 (HK2) is a therapeutic target for VDA-1102. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of VDA-1102 through regulating the expression of Hexokinase-2 (HK2). | [118], [132] | ||
Insulin-like growth factor I receptor (IGF1R)
Mecasermin [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Mecasermin. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Mecasermin through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [134] | ||
Somatomedin-1 [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Somatomedin-1. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Somatomedin-1 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [18], [133] | ||
Teprotumumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Teprotumumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Teprotumumab through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [135] | ||
Rinfabate [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Rinfabate. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Rinfabate through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [136] | ||
AMG 479 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AMG 479. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AMG 479 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [11], [133] | ||
AXL-1717 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AXL-1717. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AXL-1717 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [137] | ||
Cixutumumab [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Cixutumumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Cixutumumab through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [138] | ||
MM-141 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for MM-141. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MM-141 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [139] | ||
R1507 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for R1507. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of R1507 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [140] | ||
TT-100 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for TT-100. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of TT-100 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [141] | ||
VPI-2690B [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for VPI-2690B. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of VPI-2690B through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [142] | ||
AEW-541 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AEW-541. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AEW-541 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [143] | ||
BIIB 022 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BIIB 022. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BIIB 022 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [144] | ||
Cyclolignan picropodophyllin [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Cyclolignan picropodophyllin. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Cyclolignan picropodophyllin through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [21], [133] | ||
FPI-1434 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for FPI-1434. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of FPI-1434 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [145] | ||
HF-0299 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for HF-0299. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of HF-0299 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [146] | ||
RG-7010 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for RG-7010. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of RG-7010 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [147] | ||
ATL-1101 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for ATL-1101. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ATL-1101 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [148] | ||
BMS-695735 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BMS-695735. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BMS-695735 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [149] | ||
4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4-((1H-indazol-6-ylamino)methyl)benzene-1,2-diol through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [150] | ||
4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4-((naphthalen-2-ylamino)methyl)benzene-1,2-diol through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [151] | ||
AG 1024 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AG 1024. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AG 1024 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [152] | ||
Alpha-D-Mannose [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Alpha-D-Mannose. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Alpha-D-Mannose through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [112], [133] | ||
AMP-PNP [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AMP-PNP. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AMP-PNP through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [112], [133] | ||
AZD3463 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AZD3463. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AZD3463 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [153] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for BMS 536924. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BMS 536924 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [150] | ||
Fucose [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Fucose. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Fucose through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [154] | ||
GSK-1838705A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for GSK-1838705A. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of GSK-1838705A through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [155] | ||
GSK1511931 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for GSK1511931. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of GSK1511931 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [156] | ||
JB-1 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for JB-1. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of JB-1 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [157] | ||
NVP-ADW742 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for NVP-ADW742. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of NVP-ADW742 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [154] | ||
PQ401 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for PQ401. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PQ401 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [158] | ||
AVE-1642 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for AVE-1642. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AVE-1642 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [159] | ||
Figitumumab [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for Figitumumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Figitumumab through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [45], [133] | ||
KW-2450 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Insulin-like growth factor I receptor (IGF1R) is a therapeutic target for KW-2450. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of KW-2450 through regulating the expression of Insulin-like growth factor I receptor (IGF1R). | [133], [160] | ||
Interleukin-1 beta (IL1B)
Canakinumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Canakinumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Canakinumab through regulating the expression of Interleukin-1 beta (IL1B). | [95], [161] | ||
Diacerein [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Diacerein. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Diacerein through regulating the expression of Interleukin-1 beta (IL1B). | [95], [162] | ||
Gallium nitrate [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Gallium nitrate. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Gallium nitrate through regulating the expression of Interleukin-1 beta (IL1B). | [95], [163] | ||
Glucosamine [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Glucosamine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Glucosamine through regulating the expression of Interleukin-1 beta (IL1B). | [95], [164] | ||
Rilonacept [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Rilonacept. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Rilonacept through regulating the expression of Interleukin-1 beta (IL1B). | [95], [165] | ||
XOMA 052 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for XOMA 052. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of XOMA 052 through regulating the expression of Interleukin-1 beta (IL1B). | [95], [166] | ||
ABT-981 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for ABT-981. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ABT-981 through regulating the expression of Interleukin-1 beta (IL1B). | [95], [139] | ||
AC-201 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for AC-201. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AC-201 through regulating the expression of Interleukin-1 beta (IL1B). | [95], [167] | ||
LY-2189102 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for LY-2189102. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of LY-2189102 through regulating the expression of Interleukin-1 beta (IL1B). | [95], [168] | ||
CYT-013-IL1bQb [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for CYT-013-IL1bQb. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CYT-013-IL1bQb through regulating the expression of Interleukin-1 beta (IL1B). | [95], [169] | ||
TT-301 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for TT-301. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of TT-301 through regulating the expression of Interleukin-1 beta (IL1B). | [95], [170] | ||
Celastrol [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for Celastrol. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Celastrol through regulating the expression of Interleukin-1 beta (IL1B). | [95], [171] | ||
DVD-Ig [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for DVD-Ig. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of DVD-Ig through regulating the expression of Interleukin-1 beta (IL1B). | [95], [172] | ||
CDP-484 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Interleukin-1 beta (IL1B) is a therapeutic target for CDP-484. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CDP-484 through regulating the expression of Interleukin-1 beta (IL1B). | [95], [173] | ||
Proto-oncogene c-Myc (MYC)
AVI-5126 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for AVI-5126. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AVI-5126 through regulating the expression of Proto-oncogene c-Myc (MYC). | [174], [175] | ||
Resten-NG [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for Resten-NG. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Resten-NG through regulating the expression of Proto-oncogene c-Myc (MYC). | [174], [176] | ||
TWS-119 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Proto-oncogene c-Myc (MYC) is a therapeutic target for TWS-119. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of TWS-119 through regulating the expression of Proto-oncogene c-Myc (MYC). | [174], [177] | ||
RAC-alpha serine/threonine-protein kinase (AKT1)
AZD5363 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for AZD5363. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AZD5363 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [18], [95] | ||
Enzastaurin [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Enzastaurin. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Enzastaurin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [178] | ||
GDC-0068 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GDC-0068. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of GDC-0068 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [18], [95] | ||
ARQ 092 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 092. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ARQ 092 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [179] | ||
CI-1033 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1033. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CI-1033 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [18], [95] | ||
CMX-2043 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CMX-2043. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CMX-2043 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [21], [95] | ||
GSK2110183 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for GSK2110183. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of GSK2110183 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [180] | ||
PTX-200 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for PTX-200. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PTX-200 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [18], [95] | ||
RX-0201 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RX-0201. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of RX-0201 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [181] | ||
Triciribine prodrug [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Triciribine prodrug. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Triciribine prodrug through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [182] | ||
ARQ 751 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ARQ 751. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ARQ 751 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [181] | ||
BMS-754807 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS-754807. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BMS-754807 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [183] | ||
M2698 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for M2698. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of M2698 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [18], [95] | ||
(Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of (Z)-3-((1H-pyrrol-2-yl)methylene)indolin-2-one through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [106] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [107] | ||
4,5,6-trihydroxy-3-methylphthalide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for 4,5,6-trihydroxy-3-methylphthalide. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4,5,6-trihydroxy-3-methylphthalide through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [106] | ||
A-443654 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-443654. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of A-443654 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [106] | ||
A-674563 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for A-674563. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of A-674563 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [184] | ||
Akt inhibitor VIII [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Akt inhibitor VIII. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Akt inhibitor VIII through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [112] | ||
ALM-301 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for ALM-301. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ALM-301 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [156] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Bisindolylmaleimide-I. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [185] | ||
BMS 536924 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BMS 536924. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BMS 536924 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [106] | ||
BX-517 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for BX-517. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BX-517 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [113] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for CI-1040. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CI-1040 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [181] | ||
Inositol 1,3,4,5-Tetrakisphosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Inositol 1,3,4,5-Tetrakisphosphate. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Inositol 1,3,4,5-Tetrakisphosphate through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [186] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for KN-62. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of KN-62 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [185] | ||
Lactoquinomycin [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Lactoquinomycin. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Lactoquinomycin through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [187] | ||
LD-101 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for LD-101. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of LD-101 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [181] | ||
MYRIOCIN [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for MYRIOCIN. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MYRIOCIN through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [188] | ||
NU-1001-41 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for NU-1001-41. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of NU-1001-41 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [181] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for RO-316233. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of RO-316233 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [106] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Ro31-8220. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Ro31-8220 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [189] | ||
SB-747651A [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for SB-747651A. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of SB-747651A through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [89], [95] | ||
STAUROSPORINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for STAUROSPORINONE. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of STAUROSPORINONE through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [188] | ||
VLI-27 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for VLI-27. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of VLI-27 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [95], [181] | ||
Squalestatin 1 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | RAC-alpha serine/threonine-protein kinase (AKT1) is a therapeutic target for Squalestatin 1. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Squalestatin 1 through regulating the expression of RAC-alpha serine/threonine-protein kinase (AKT1). | [18], [95] | ||
Stress-activated protein kinase 2a (p38 alpha)
Ozagrel [Phase 4]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Ozagrel. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Ozagrel through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [190] | ||
Losmapimod [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Losmapimod. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Losmapimod through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [191] | ||
Dilmapimod [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Dilmapimod. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Dilmapimod through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [192] | ||
VX-702 [Phase 2a]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for VX-702. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of VX-702 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [17], [95] | ||
VX-745 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for VX-745. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of VX-745 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [193] | ||
(5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for (5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of (5-amino-1-phenyl-1H-pyrazol-4-yl)phenylmethanone through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [194] | ||
2-Chlorophenol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 2-Chlorophenol. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 2-Chlorophenol through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [127] | ||
3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 3-(1-NAPHTHYLMETHOXY)PYRIDIN-2-AMINE through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [112] | ||
3-(Benzyloxy)Pyridin-2-Amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 3-(Benzyloxy)Pyridin-2-Amine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 3-(Benzyloxy)Pyridin-2-Amine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [112] | ||
4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4,5,6,7-tetrabromo-1H-benzo[d][1,2,3]triazole through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [195] | ||
4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4-(2-Ethyl-4-m-tolyl-thiazol-5-yl)-pyridine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [196] | ||
4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4-PHENOXY-N-(PYRIDIN-2-YLMETHYL)BENZAMIDE through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [127] | ||
4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 4-Phenylsulfanyl-7H-pyrrolo[2,3-d]pyrimidine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [110] | ||
6-(4-Fluoro-phenylsulfanyl)-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 6-(4-Fluoro-phenylsulfanyl)-9H-purine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 6-(4-Fluoro-phenylsulfanyl)-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [110] | ||
6-Benzylsulfanyl-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 6-Benzylsulfanyl-9H-purine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 6-Benzylsulfanyl-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [106] | ||
6-o-tolylquinazolin-2-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 6-o-tolylquinazolin-2-amine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 6-o-tolylquinazolin-2-amine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [197] | ||
6-Phenylsulfanyl-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 6-Phenylsulfanyl-9H-purine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 6-Phenylsulfanyl-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [110] | ||
9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 9-(4-Fluoro-benzyl)-6-phenylsulfanyl-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [198] | ||
9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 9-Benzyl-6-(4-fluoro-phenylsulfanyl)-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [110] | ||
9-Benzyl-6-phenylsulfanyl-9H-purine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for 9-Benzyl-6-phenylsulfanyl-9H-purine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 9-Benzyl-6-phenylsulfanyl-9H-purine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [110] | ||
AG1478 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for AG1478. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AG1478 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [199] | ||
B-Octylglucoside [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for B-Octylglucoside. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of B-Octylglucoside through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [200] | ||
Bisindolylmaleimide-I [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Bisindolylmaleimide-I. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Bisindolylmaleimide-I through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [110] | ||
CI-1040 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for CI-1040. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CI-1040 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [201] | ||
Dihydro-quinolinone [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Dihydro-quinolinone. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Dihydro-quinolinone through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [202] | ||
DP-802 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for DP-802. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of DP-802 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [190] | ||
GSK-280 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for GSK-280. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of GSK-280 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [203] | ||
GW-788388 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for GW-788388. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of GW-788388 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [106] | ||
IN-1130 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for IN-1130. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of IN-1130 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [204] | ||
IN-1166 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for IN-1166. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of IN-1166 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [113] | ||
KN-62 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for KN-62. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of KN-62 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [202] | ||
KT-5720 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for KT-5720. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of KT-5720 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [205] | ||
L-779450 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for L-779450. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of L-779450 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [107] | ||
ML-3163 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for ML-3163. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ML-3163 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [206] | ||
ML-3375 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for ML-3375. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ML-3375 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [207] | ||
ML-3403 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for ML-3403. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ML-3403 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [106] | ||
N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of N-(3-(trifluoromethoxy)benzyl)-4-phenoxybenzamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [208] | ||
N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of N-(3-(trifluoromethyl)benzyl)-4-phenoxybenzamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [208] | ||
N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of N-(4-(trifluoromethyl)benzyl)-4-phenoxybenzamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [208] | ||
N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of N-(4-fluorobenzyl)-N-(pyridin-4-yl)-2-naphthamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [106] | ||
N-(4-methyl-benzyl)-4-phenoxy-benzamide [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for N-(4-methyl-benzyl)-4-phenoxy-benzamide. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of N-(4-methyl-benzyl)-4-phenoxy-benzamide through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [209] | ||
Oxindole 94 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Oxindole 94. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Oxindole 94 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [208] | ||
PD-0166326 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for PD-0166326. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PD-0166326 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [210] | ||
PD-0173956 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for PD-0173956. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PD-0173956 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [197] | ||
PHA-666859 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for PHA-666859. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PHA-666859 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [190] | ||
Phenyl-(3-phenyl-1H-indazol-6-yl)-amine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Phenyl-(3-phenyl-1H-indazol-6-yl)-amine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Phenyl-(3-phenyl-1H-indazol-6-yl)-amine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [106] | ||
RO-316233 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for RO-316233. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of RO-316233 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [110] | ||
Ro-3201195 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Ro-3201195. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Ro-3201195 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [211] | ||
Ro31-8220 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Ro31-8220. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Ro31-8220 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [210] | ||
RWJ-68354 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for RWJ-68354. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of RWJ-68354 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [206] | ||
SB-216995 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB-216995. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of SB-216995 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [212] | ||
SB-218655 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB-218655. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of SB-218655 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [197] | ||
SB-227931 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB-227931. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of SB-227931 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [213] | ||
Small molecule 34 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Small molecule 34. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Small molecule 34 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [112] | ||
STAUROSPORINONE [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for STAUROSPORINONE. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of STAUROSPORINONE through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [106] | ||
Talmapimod [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Talmapimod. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Talmapimod through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [127] | ||
Triazolopyridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for Triazolopyridine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Triazolopyridine through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [127] | ||
UCB-1277763 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for UCB-1277763. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of UCB-1277763 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [190] | ||
ZM-336372 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for ZM-336372. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ZM-336372 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [214] | ||
FR167653 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for FR167653. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of FR167653 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [17], [95] | ||
PAMAPIMOD [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for PAMAPIMOD. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PAMAPIMOD through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [17], [95] | ||
R-1487 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for R-1487. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of R-1487 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [192] | ||
SB 203580 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB 203580. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of SB 203580 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [215] | ||
SB 235699 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB 235699. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of SB 235699 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [216] | ||
SB-242235 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB-242235. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of SB-242235 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [217] | ||
SB220025 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SB220025. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of SB220025 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [218] | ||
SC-102 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Stress-activated protein kinase 2a (p38 alpha) is a therapeutic target for SC-102. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of SC-102 through regulating the expression of Stress-activated protein kinase 2a (p38 alpha). | [95], [112] | ||
Thymidine kinase 1 (TK1)
DEOXYCYTIDINE [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for DEOXYCYTIDINE. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of DEOXYCYTIDINE through regulating the expression of Thymidine kinase 1 (TK1). | [112], [117] | ||
Penciclovir [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Penciclovir. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Penciclovir through regulating the expression of Thymidine kinase 1 (TK1). | [117], [219] | ||
TK-DLI [Preregistration]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for TK-DLI. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of TK-DLI through regulating the expression of Thymidine kinase 1 (TK1). | [112], [117] | ||
FV-100 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for FV-100. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of FV-100 through regulating the expression of Thymidine kinase 1 (TK1). | [117], [220] | ||
Radiosensitizer gene therapy [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Radiosensitizer gene therapy. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Radiosensitizer gene therapy through regulating the expression of Thymidine kinase 1 (TK1). | [117], [221] | ||
RP101 [Phase 2/3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for RP101. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of RP101 through regulating the expression of Thymidine kinase 1 (TK1). | [112], [117] | ||
HQK-1004 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for HQK-1004. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of HQK-1004 through regulating the expression of Thymidine kinase 1 (TK1). | [117], [222] | ||
Rilapladib [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Rilapladib. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Rilapladib through regulating the expression of Thymidine kinase 1 (TK1). | [117], [223] | ||
Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Thymidine kinase-expressing adenovirus and ganciclovir suicide gene therapy through regulating the expression of Thymidine kinase 1 (TK1). | [117], [224] | ||
(South)-Methanocarba-Thymidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for (South)-Methanocarba-Thymidine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of (South)-Methanocarba-Thymidine through regulating the expression of Thymidine kinase 1 (TK1). | [112], [117] | ||
1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 1-[(Z)-4-(triphenylmethoxy)-2-butenyl]thymine through regulating the expression of Thymidine kinase 1 (TK1). | [117], [225] | ||
1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 1-[2-(2-triphenylmethoxyethoxy)ethyl]thymine through regulating the expression of Thymidine kinase 1 (TK1). | [117], [225] | ||
1-[5-(triphenylmethoxy)pentyl]thymine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 1-[5-(triphenylmethoxy)pentyl]thymine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 1-[5-(triphenylmethoxy)pentyl]thymine through regulating the expression of Thymidine kinase 1 (TK1). | [117], [225] | ||
1-[6-(triphenylmethoxy)hexyl]thymine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 1-[6-(triphenylmethoxy)hexyl]thymine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 1-[6-(triphenylmethoxy)hexyl]thymine through regulating the expression of Thymidine kinase 1 (TK1). | [117], [225] | ||
1-[7-(triphenylmethoxy)heptyl]thymine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 1-[7-(triphenylmethoxy)heptyl]thymine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 1-[7-(triphenylmethoxy)heptyl]thymine through regulating the expression of Thymidine kinase 1 (TK1). | [117], [226] | ||
2'-deoxythymidine triphosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 2'-deoxythymidine triphosphate. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 2'-deoxythymidine triphosphate through regulating the expression of Thymidine kinase 1 (TK1). | [117], [223] | ||
2'-Deoxyuridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 2'-Deoxyuridine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 2'-Deoxyuridine through regulating the expression of Thymidine kinase 1 (TK1). | [117], [227] | ||
3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 3'-(1,2,3-Triazol-1-yl)-3'-deoxy-beta-D-thymidine through regulating the expression of Thymidine kinase 1 (TK1). | [117], [219] | ||
3-(2-propyn-1-yl)thymidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 3-(2-propyn-1-yl)thymidine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 3-(2-propyn-1-yl)thymidine through regulating the expression of Thymidine kinase 1 (TK1). | [117], [228] | ||
5-Bromothienyldeoxyuridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 5-Bromothienyldeoxyuridine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 5-Bromothienyldeoxyuridine through regulating the expression of Thymidine kinase 1 (TK1). | [112], [117] | ||
5-Iodo-2'-Deoxyuridine-5'-Monophosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 5-Iodo-2'-Deoxyuridine-5'-Monophosphate. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 5-Iodo-2'-Deoxyuridine-5'-Monophosphate through regulating the expression of Thymidine kinase 1 (TK1). | [112], [117] | ||
5-propyl-2'-deoxyuridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 5-propyl-2'-deoxyuridine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 5-propyl-2'-deoxyuridine through regulating the expression of Thymidine kinase 1 (TK1). | [117], [228] | ||
6-(Dihydroxy-Isobutyl)-Thymine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 6-(Dihydroxy-Isobutyl)-Thymine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 6-(Dihydroxy-Isobutyl)-Thymine through regulating the expression of Thymidine kinase 1 (TK1). | [112], [117] | ||
6-Hydroxypropylthymine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 6-Hydroxypropylthymine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 6-Hydroxypropylthymine through regulating the expression of Thymidine kinase 1 (TK1). | [117], [229] | ||
9-(4-Hydroxybutyl)-N2-Phenylguanine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 9-(4-Hydroxybutyl)-N2-Phenylguanine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 9-(4-Hydroxybutyl)-N2-Phenylguanine through regulating the expression of Thymidine kinase 1 (TK1). | [112], [117] | ||
9-Hydroxypropyladenine, R-Isomer [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 9-Hydroxypropyladenine, R-Isomer. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 9-Hydroxypropyladenine, R-Isomer through regulating the expression of Thymidine kinase 1 (TK1). | [112], [117] | ||
9-Hydroxypropyladenine, S-Isomer [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for 9-Hydroxypropyladenine, S-Isomer. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 9-Hydroxypropyladenine, S-Isomer through regulating the expression of Thymidine kinase 1 (TK1). | [112], [117] | ||
BVDU-MP [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for BVDU-MP. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BVDU-MP through regulating the expression of Thymidine kinase 1 (TK1). | [117], [230] | ||
Deoxythymidine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Deoxythymidine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Deoxythymidine through regulating the expression of Thymidine kinase 1 (TK1). | [112], [117] | ||
Edoxudine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Edoxudine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Edoxudine through regulating the expression of Thymidine kinase 1 (TK1). | [117], [228] | ||
ITdU [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for ITdU. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ITdU through regulating the expression of Thymidine kinase 1 (TK1). | [117], [225] | ||
L-5-(bromovinyl)deoxyuridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for L-5-(bromovinyl)deoxyuridine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of L-5-(bromovinyl)deoxyuridine through regulating the expression of Thymidine kinase 1 (TK1). | [117], [231] | ||
L-5-iodo-2'-deoxyuridine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for L-5-iodo-2'-deoxyuridine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of L-5-iodo-2'-deoxyuridine through regulating the expression of Thymidine kinase 1 (TK1). | [117], [228] | ||
N2-(3-trifluoromethylphenyl)guanine [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for N2-(3-trifluoromethylphenyl)guanine. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of N2-(3-trifluoromethylphenyl)guanine through regulating the expression of Thymidine kinase 1 (TK1). | [117], [228] | ||
P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of P1-(5'-Adenosyl)P5-(5'-Thymidyl)Pentaphosphate through regulating the expression of Thymidine kinase 1 (TK1). | [112], [117] | ||
Thymidine-5'-Phosphate [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Thymidine-5'-Phosphate. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Thymidine-5'-Phosphate through regulating the expression of Thymidine kinase 1 (TK1). | [112], [117] | ||
Sitimagene ceradenovec [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Thymidine kinase 1 (TK1) is a therapeutic target for Sitimagene ceradenovec. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Sitimagene ceradenovec through regulating the expression of Thymidine kinase 1 (TK1). | [117], [232] | ||
Tumor necrosis factor (TNF)
Adalimumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Adalimumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Adalimumab through regulating the expression of Tumor necrosis factor (TNF). | [95], [233] | ||
Certolizumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Certolizumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Certolizumab through regulating the expression of Tumor necrosis factor (TNF). | [95], [234] | ||
Enbrel [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Enbrel. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Enbrel through regulating the expression of Tumor necrosis factor (TNF). | [95], [235] | ||
Etanercept [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Etanercept. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Etanercept through regulating the expression of Tumor necrosis factor (TNF). | [95], [236] | ||
Golimumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Golimumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Golimumab through regulating the expression of Tumor necrosis factor (TNF). | [95], [237] | ||
Infliximab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Infliximab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Infliximab through regulating the expression of Tumor necrosis factor (TNF). | [95], [238] | ||
Lenalidomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Lenalidomide. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Lenalidomide through regulating the expression of Tumor necrosis factor (TNF). | [95], [164] | ||
Nafamostat [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Nafamostat. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Nafamostat through regulating the expression of Tumor necrosis factor (TNF). | [95], [239] | ||
Pentoxifylline [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Pentoxifylline. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Pentoxifylline through regulating the expression of Tumor necrosis factor (TNF). | [95], [240] | ||
Thalidomide [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Thalidomide. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Thalidomide through regulating the expression of Tumor necrosis factor (TNF). | [36], [95] | ||
ABP 501 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABP 501. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ABP 501 through regulating the expression of Tumor necrosis factor (TNF). | [95], [241] | ||
CPL-7075 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CPL-7075. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CPL-7075 through regulating the expression of Tumor necrosis factor (TNF). | [95], [242] | ||
Golnerminogene pradenovac [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Golnerminogene pradenovac. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Golnerminogene pradenovac through regulating the expression of Tumor necrosis factor (TNF). | [95], [243] | ||
PF-06410293 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-06410293. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PF-06410293 through regulating the expression of Tumor necrosis factor (TNF). | [95], [244] | ||
PF-06438179 [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-06438179. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PF-06438179 through regulating the expression of Tumor necrosis factor (TNF). | [95], [245] | ||
ABT-122 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABT-122. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ABT-122 through regulating the expression of Tumor necrosis factor (TNF). | [95], [246] | ||
AN0128 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AN0128. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AN0128 through regulating the expression of Tumor necrosis factor (TNF). | [95], [247] | ||
AP-301-IH [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AP-301-IH. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AP-301-IH through regulating the expression of Tumor necrosis factor (TNF). | [95], [248] | ||
ART621 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ART621. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ART621 through regulating the expression of Tumor necrosis factor (TNF). | [33], [95] | ||
BAICALEIN [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for BAICALEIN. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of BAICALEIN through regulating the expression of Tumor necrosis factor (TNF). | [95], [249] | ||
COVA322 [Phase 1/2a]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for COVA322. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of COVA322 through regulating the expression of Tumor necrosis factor (TNF). | [95], [250] | ||
DLX-105 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for DLX-105. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of DLX-105 through regulating the expression of Tumor necrosis factor (TNF). | [95], [251] | ||
ESBA-105 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ESBA-105. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ESBA-105 through regulating the expression of Tumor necrosis factor (TNF). | [95], [252] | ||
Ortataxel [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Ortataxel. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Ortataxel through regulating the expression of Tumor necrosis factor (TNF). | [95], [253] | ||
Pegsunercept [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Pegsunercept. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Pegsunercept through regulating the expression of Tumor necrosis factor (TNF). | [95], [254] | ||
RDP58 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for RDP58. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of RDP58 through regulating the expression of Tumor necrosis factor (TNF). | [95], [255] | ||
TNF alpha kinoid [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for TNF alpha kinoid. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of TNF alpha kinoid through regulating the expression of Tumor necrosis factor (TNF). | [95], [256] | ||
ABBV-257 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABBV-257. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ABBV-257 through regulating the expression of Tumor necrosis factor (TNF). | [95], [257] | ||
AST-005 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AST-005. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AST-005 through regulating the expression of Tumor necrosis factor (TNF). | [95], [258] | ||
AVX-470 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AVX-470. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AVX-470 through regulating the expression of Tumor necrosis factor (TNF). | [95], [258] | ||
CYT-609 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CYT-609. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CYT-609 through regulating the expression of Tumor necrosis factor (TNF). | [95], [259] | ||
INB03 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for INB03. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of INB03 through regulating the expression of Tumor necrosis factor (TNF). | [95], [260] | ||
PF-05230905 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PF-05230905. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PF-05230905 through regulating the expression of Tumor necrosis factor (TNF). | [95], [261] | ||
PMI-005 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PMI-005. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PMI-005 through regulating the expression of Tumor necrosis factor (TNF). | [95], [262] | ||
ABX-0401 [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ABX-0401. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ABX-0401 through regulating the expression of Tumor necrosis factor (TNF). | [95], [172] | ||
Celastrol [Preclinical]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Celastrol. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Celastrol through regulating the expression of Tumor necrosis factor (TNF). | [45], [95] | ||
2-Propanol, Isopropanol [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for 2-Propanol, Isopropanol. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of 2-Propanol, Isopropanol through regulating the expression of Tumor necrosis factor (TNF). | [95], [263] | ||
DOM-0215 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for DOM-0215. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of DOM-0215 through regulating the expression of Tumor necrosis factor (TNF). | [95], [264] | ||
IK-862 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for IK-862. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of IK-862 through regulating the expression of Tumor necrosis factor (TNF). | [95], [265] | ||
PKF-241-466 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PKF-241-466. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PKF-241-466 through regulating the expression of Tumor necrosis factor (TNF). | [95], [265] | ||
PKF-242-484 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PKF-242-484. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PKF-242-484 through regulating the expression of Tumor necrosis factor (TNF). | [95], [266] | ||
Y-39041 [Investigative]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Y-39041. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Y-39041 through regulating the expression of Tumor necrosis factor (TNF). | [95], [267] | ||
ALS-00T2-0501 [Discontinued in Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ALS-00T2-0501. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ALS-00T2-0501 through regulating the expression of Tumor necrosis factor (TNF). | [95], [268] | ||
AME-527 [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for AME-527. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of AME-527 through regulating the expression of Tumor necrosis factor (TNF). | [95], [264] | ||
Camobucol [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Camobucol. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Camobucol through regulating the expression of Tumor necrosis factor (TNF). | [95], [269] | ||
CDP571 [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CDP571. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CDP571 through regulating the expression of Tumor necrosis factor (TNF). | [95], [270] | ||
CRx-191 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CRx-191. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CRx-191 through regulating the expression of Tumor necrosis factor (TNF). | [95], [271] | ||
CYT-007-TNFQb [Discontinued in Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for CYT-007-TNFQb. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of CYT-007-TNFQb through regulating the expression of Tumor necrosis factor (TNF). | [95], [272] | ||
FR-133605 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for FR-133605. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of FR-133605 through regulating the expression of Tumor necrosis factor (TNF). | [95], [273] | ||
ISIS 104838 [Discontinued in Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for ISIS 104838. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ISIS 104838 through regulating the expression of Tumor necrosis factor (TNF). | [95], [274] | ||
MDL-201112 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for MDL-201112. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MDL-201112 through regulating the expression of Tumor necrosis factor (TNF). | [95], [275] | ||
PNU-282987 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for PNU-282987. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PNU-282987 through regulating the expression of Tumor necrosis factor (TNF). | [95], [276] | ||
Segard [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for Segard. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Segard through regulating the expression of Tumor necrosis factor (TNF). | [95], [277] | ||
TNFQb therapeutic vaccines [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Tumor necrosis factor (TNF) is a therapeutic target for TNFQb therapeutic vaccines. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of TNFQb therapeutic vaccines through regulating the expression of Tumor necrosis factor (TNF). | [95], [278] | ||
Vascular endothelial growth factor A (VEGFA)
Aflibercept [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Aflibercept. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Aflibercept through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [279] | ||
Bevacizumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Bevacizumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Bevacizumab through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [280] | ||
Brolucizumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Brolucizumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Brolucizumab through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [281] | ||
Ranibizumab [Approved]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Ranibizumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Ranibizumab through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [282] | ||
Faricimab [Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Faricimab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Faricimab through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [283] | ||
Abicipar pegol [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Abicipar pegol. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Abicipar pegol through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [284] | ||
MP0250 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for MP0250. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MP0250 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [285] | ||
PTC299 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for PTC299. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of PTC299 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [286] | ||
RG7221 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for RG7221. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of RG7221 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [33] | ||
RO5520985 [Phase 2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for RO5520985. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of RO5520985 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [139] | ||
SNN-0029 [Phase 1/2]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for SNN-0029. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of SNN-0029 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [18] | ||
ABI-011 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for ABI-011. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ABI-011 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [287] | ||
MP-0112 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for MP-0112. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of MP-0112 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [288] | ||
Navicixizumab [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Navicixizumab. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Navicixizumab through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [18] | ||
SFLT-01 [Phase 1]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for SFLT-01. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of SFLT-01 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [35] | ||
ALN-VEG01 [Terminated]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for ALN-VEG01. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of ALN-VEG01 through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [182] | ||
Bevasiranib [Discontinued in Phase 3]
| In total 1 mechanisms lead to this potential drug response | ||||
| Response Summary | Vascular endothelial growth factor A (VEGFA) is a therapeutic target for Bevasiranib. The Insulin-like growth factor 2 mRNA-binding protein 2 (IGF2BP2) has potential in affecting the response of Bevasiranib through regulating the expression of Vascular endothelial growth factor A (VEGFA). | [1], [280] | ||
References